ArticleScientific reports2023
Long-term outcomes of Baerveldt glaucoma implant surgery in Japanese patients.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- The Duke Baerveldt 350 Versus Ahmed ClearPath 350 Study (DBACS): A Randomized Control Trial In Adults With Medically Refractory Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Two-year efficacy and safety outcomes of the Paul Glaucoma Implant compared to the Ahmed Glaucoma Valve.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Clinical Outcomes and Risk Factors for Surgical Failure Following Baerveldt Glaucoma Implant Surgery as a Primary Filtering Procedure.Journal of clinical medicine · 2026Article
- First-in-human implantation of a self-adjustable glaucoma drainage device (eyeValve): safety and performance in blind eyes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Risk Factors for Postoperative Hyphema Following Baerveldt Glaucoma Implant Surgery: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Choroidal Detachment After Baerveldt Glaucoma Implant Surgery: Incidence and Risk Factors.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Long-term outcomes of Baerveldt glaucoma implants with the scleral flap and patch technique and vitreous cavity insertion: a 5-year follow-up.International ophthalmology · 2025Article
- Efficacy and safety outcomes of the Paul glaucoma implant compared to the Ahmed glaucoma valve.Scientific reports · 2025Article
- Surgical Outcomes of Baerveldt Glaucoma Implant Versus Ahmed Glaucoma Valve in Neovascular Glaucoma: A Retrospective Multicenter Study.Advances in therapy · 2025Article
- Characterization of the visually impaired patients with diabetes mellitus in Japan.Journal of diabetes investigation · 2024Article
- Surgical Treatment of Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy in Japanese Patients without the Use of Glaucoma Drainage Devices.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the long-term surgical outcomes of Baerveldt glaucoma implant (BGI) surgery in patients with refractory glaucoma (204 eyes/204 patients). Surgical failure was defined by: < 20% reduction in preoperative intraocular pressure (IOP), or criterion A (IOP > 21 mmHg), criterion B (IOP > 17 mmHg), or criterion C (IOP > 14 mmHg). Reoperation, loss of light perception vision, or hypotony also denoted failure. The probability of success at 5 years postoperatively using criteria A, B, and C was 72.4%, 49.7%, and 24.4%, respectively. The mean IOP decreased significantly from 32.7 ± 9.7 mmHg preoperatively to 13.1 ± 3.9 mmHg at 5 years; the mean number of glaucoma medications also decreased from 3.7 ± 1.2 to 1.8 ± 1.9 (both P < 0.01). The number of previous intraocular surgeries was significantly associated with failure in the multivariable analysis for criterion B (hazard ratio 1.30; P < 0.01) and criterion C (hazard ratio 1.19; P = 0.031). Early and late postoperative complications occurred in 82 (40.2%) and 28 (13.7%) eyes, respectively. Postoperative interventions were performed in 44 eyes (21.6%). BGI surgery resulted in significant long-term decreases in IOP and the number of glaucoma medications. BGI surgery is effective for refractory glaucoma. However, postoperative interventions due to complications are required in numerous cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.